GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Upper GI Tract/Magnetic Sphincter Augmentation Provides Durable GERD Control : Ann Surg | Jun 2026
7

Magnetic Sphincter Augmentation Provides Durable GERD Control : Ann Surg | Jun 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated June 1, 2026

Introduction:

Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving physiologic swallowing and venting mechanisms, MSA offers a less disruptive alternative to traditional antireflux surgery. Although short- and intermediate-term outcomes have been favorable, robust long-term data have been limited.

Problem Statement:

For any implantable antireflux device, long-term durability, symptom control, dependence on acid-suppressive medications, and device-related complications are critical considerations. Questions remain regarding the sustainability of reflux control beyond five years and the frequency of device removal or adverse events over time.

Summary:

This FDA post-approval study provides important long-term evidence on the effectiveness and safety of magnetic sphincter augmentation in patients with GERD. At more than five years of follow-up, most patients experienced sustained and clinically meaningful improvement in reflux-related quality of life, with the vast majority remaining free from daily proton pump inhibitor use. Objective testing confirmed durable reflux control, demonstrating persistent normalization of esophageal acid exposure in a substantial proportion of patients. A notable advantage of MSA was preservation of physiologic functions such as belching and vomiting, which are often impaired after conventional fundoplication. Dysphagia remained uncommon and generally manageable. Device-related complications were infrequent, with erosion occurring rarely. However, approximately one in eight patients required device explantation during long-term follow-up. Reassuringly, most patients who underwent device removal achieved symptom resolution through explantation alone, conversion to fundoplication, or device replacement. These findings demonstrate that MSA provides durable long-term control of GERD symptoms and reduces dependence on acid-suppressive medication while maintaining favorable functional outcomes. Although a minority of patients may ultimately require device removal, the overall long-term safety and efficacy profile supports MSA as an established surgical option for appropriately selected patients with chronic GERD.

Related Q&A

08

New Strategies Needed for Resistant H. pylori : Indian J Gastroenterol | Jun 2026

Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful...

09

Vonoprazan–Tetracycline Dual Therapy Simplifies H. pylori Rescue Treatment : Gastroenterology | June 2026

Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates....

10

H. pylori Eradication Reduces Cancer but Mortality Benefit Remains Fragile : Gastroenterology | June 2026

Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following...

11

Vonoprazan Triple and Reverse Hybrid Regimens Outperform High-Dose Dual Therapy for H. pylori : AJG | May 2026

Introduction Helicobacter pylori Infection remains a major global cause of peptic ulcer disease, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Rising antimicrobial resistance, particularly to clarithromycin, has progressively...

12

BRTO and TIPS Outperform Cyanoacrylate for Secondary GV Bleeding Prevention : Meta-analysis | May 2026

Introduction Gastric Varices are associated with severe hemorrhage, high transfusion requirements and substantial mortality in patients with Cirrhosis. Compared with esophageal varices, gastric varices bleed less frequently but...

13

Guideline Gaps in Paediatric H. pylori Care : Frontline Gastroenterol | May 2026

Introduction Helicobacter pylori infection remains an important paediatric gastrointestinal infection worldwide, yet its diagnosis and treatment in children differ substantially from adult practice. The joint ESPGHAN–NASPGHAN guidelines advocate...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer